{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:40:43Z","timestamp":1792838443724,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2019YFC0840605"],"award-info":[{"award-number":["2019YFC0840605"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.exphem.2026.105871","type":"journal-article","created":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T06:01:59Z","timestamp":1789279319000},"page":"105871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effect of the dominant-negative Ikaros isoform 6 (IK6) on cell function and drug sensitivity in Ph-positive acute lymphoblastic leukemia cell lines"],"prefix":"10.1016","volume":"164","author":[{"given":"Juan","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qishan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meizhen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5060-5070","authenticated-orcid":false,"given":"Yingchang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2026.105871_bib0001","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/cncr.29383","article-title":"New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2026.105871_bib0002","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1182\/blood.2023022919","article-title":"Genetic subtypes of B-cell acute lymphoblastic leukemia in adults","volume":"145","author":"Passet","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105871_bib0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2023023152","article-title":"How I treat adult Ph+ ALL","volume":"145","author":"Chiaretti","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105871_bib0004","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.clml.2025.06.019","article-title":"SOHO state of the art updates and next questions: Philadelphia chromosome-positive acute lymphoblastic leukemia can be treated with chemotherapy-free regimens without transplant","volume":"25","author":"Haddad","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.exphem.2026.105871_bib0005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-025-01709-y","article-title":"Molecular characterization and predictors of relapse in patients with Ph+ ALL after frontline ponatinib and blinatumomab","volume":"18","author":"Short","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2026.105871_bib0006","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1016\/j.clml.2024.06.002","article-title":"Efficacy of chemotherapy-free regimens in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"24","author":"Ali","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.exphem.2026.105871_bib0007","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature05690","article-title":"Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia","volume":"446","author":"Mullighan","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2026.105871_bib0008","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0092-8674(94)90407-3","article-title":"The Ikaros gene is required for the development of all lymphoid lineages","volume":"79","author":"Georgopoulos","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2026.105871_bib0009","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2026.105871_bib0010","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"36","author":"Stanulla","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2026.105871_bib0011","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.molimm.2011.03.006","article-title":"The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity","volume":"48","author":"John","year":"2011","journal-title":"Mol Immunol"},{"key":"10.1016\/j.exphem.2026.105871_bib0012","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/bmt.2014.281","article-title":"Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL","volume":"50","author":"Kim","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2026.105871_bib0013","first-page":"72","article-title":"Absence of genomic Ikaros\/IKZF1 deletions in pediatric B-precursor acute lymphoblastic leukemia","volume":"3","author":"Qazi","year":"2013","journal-title":"Int J Mol Med Sci"},{"key":"10.1016\/j.exphem.2026.105871_bib0014","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2013-06-509794","article-title":"IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL","volume":"123","author":"van der Veer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105871_bib0015","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1038\/s41375-025-02633-3","article-title":"Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia","volume":"39","author":"Wang\u2019ondu","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105871_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.677034","article-title":"Gene deletions and prognostic values in B-lineage acute lymphoblastic leukemia","volume":"11","author":"Fang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.exphem.2026.105871_bib0017","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/10428190801993462","article-title":"Ikaros dominant negative isoform (Ik6) induces IL-3-independent survival of murine pro-B lymphocytes by activating JAK-STAT and up-regulating Bcl-xL levels","volume":"49","author":"Kano","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2026.105871_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040934","article-title":"IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia","volume":"7","author":"Iacobucci","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2026.105871_bib0019","first-page":"1","article-title":"Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia","volume":"3","author":"Kastner","year":"2013","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.exphem.2026.105871_bib0020","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1182\/bloodadvances.2020002408","article-title":"Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities","volume":"5","author":"Rogers","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2026.105871_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.905665","article-title":"Reversal of IKZF1-induced glucocorticoid resistance by dual targeting of AKT and ERK signaling pathways","volume":"12","author":"Butler","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.exphem.2026.105871_bib0022","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1038\/leu.2016.128","article-title":"IKZF1 deletion is enriched in pediatric B-cell precursor acute lymphoblastic leukemia patients showing prednisolone resistance","volume":"30","author":"Imamura","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105871_bib0023","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/leu.2015.359","article-title":"Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia","volume":"30","author":"Marke","year":"2016","journal-title":"Leukemia"},{"issue":"Suppl 6","key":"10.1016\/j.exphem.2026.105871_bib0024","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1016\/j.htct.2024.05.004","article-title":"IKZF1 and BTG1 silencing reduces glucocorticoid response in B-cell precursor acute leukemia cell line","volume":"46","author":"De Albuquerque","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.exphem.2026.105871_bib0025","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ccell.2015.07.016","article-title":"Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia","volume":"28","author":"Churchman","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2026.105871_bib0026","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/biomedicines12010089","article-title":"IKZF1 alterations and therapeutic targeting in B-cell acute lymphoblastic leukemia","volume":"12","author":"Paolino","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.exphem.2026.105871_bib0027","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.3324\/haematol.2023.284357","article-title":"IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia","volume":"109","author":"Vervoort","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2026.105871_bib0028","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/sj.onc.1209133","article-title":"BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells","volume":"25","author":"Klein","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2026.105871_bib0029","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/ni.2821","article-title":"Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia","volume":"15","author":"Joshi","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1016\/j.exphem.2026.105871_bib0030","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2026.105871_bib0031","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.exphem.2026.105871_bib0032","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/bloodadvances.2021005978","article-title":"Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab","volume":"6","author":"Wudhikarn","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2026.105871_bib0033","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1038\/s41467-025-58868-2","article-title":"IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies","volume":"16","author":"Domizi","year":"2025","journal-title":"Nat Commun"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26005047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26005047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:30:54Z","timestamp":1792837854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X26005047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":33,"alternative-id":["S0301472X26005047"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105871","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of the dominant-negative Ikaros isoform 6 (IK6) on cell function and drug sensitivity in Ph-positive acute lymphoblastic leukemia cell lines","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105871","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Experimental Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105871"}}